Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Titel:
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Auteur:
Kümmel, Sherko Paepke, Stefan Huober, Jens Schem, Christian Untch, Michael Blohmer, Jens Uwe Eiermann, Wolfgang Gerber, Bernd Hanusch, Claus Hilfrich, Jörn Jackisch, Christian Schneeweiss, Andreas Denkert, Carsten Engels, Knut Klare, Peter Fasching, Peter A. von Minckwitz, Gunter Burchardi, Nicole Loibl, Sibylle